Oculocutaneous albinism
MONDO:0018910Oculocutaneous albinism (OCA) describes a group of inherited disorders of melanin biosynthesis characterized by a generalized reduction in pigmentation of hair, skin and eyes and variable ocular findings including nystagmus, reduced visual acuity and photophobia. Variants include OCA1A (the most severe form), OCA1B, OCA1-minimal pigment (OCA1-MP), OCA1-temperature sensitive (OCA1-TS), OCA2, OCA3, OCA4, OCA5, OCA6 and OCA7.
Also known as: OCA, non-syndromic oculocutaneous albinism, nonsyndromic oculocutaneous albinism, albinism, oculocutaneous
4 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Gene therapy injection aims to restore pigment in Children's eyes
Disease control Recruiting nowThis early-phase trial tests a single injection of JWK010 gene therapy in 18 children aged 5 to 12 with oculocutaneous albinism type 1 (OCA1). OCA1 is caused by a gene change that prevents the body from making pigment, leading to vision problems and light sensitivity. The therapy…
Phase: EARLY_PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Massive eye gene bank aims to unlock secrets of rare blindness
Knowledge-focused Recruiting nowThis study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Could serotonin explain albinism symptoms?
Knowledge-focused Recruiting nowThis study investigates whether serotonin, a chemical in the body, affects symptoms of oculocutaneous albinism in children. Researchers will measure serotonin levels in 160 children with and without albinism. The goal is to better understand the condition, not to test a new treat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:12 UTC